NEWS

We’re pleased to announce the opening of three new research studies this month: Prolong, MRD, and De-escalate. These studies represent important new avenues in our ongoing research efforts

PROLoNg: Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck: a randomized phase III study

Data gathered from this study aims to contribute to our understanding of sustained treatment benefits.

MRD: exploring better ways to detect cancer returning early

Our new MRD (Minimal Residual Disease) study is testing whether a simple blood test can detect signs of cancer coming back earlier than clinical exams or imaging. This could help doctors take action sooner and improve care after treatment.

MRD 2148 is a part of the EORTC SPECTA Platform-to find out more please follow this link.

De-escalate Study: Assessing Treatment Optimization

The De-escalate study will investigate approaches to potentially reduce treatment intensity for patients. This research seeks to determine if similar outcomes can be achieved with less intensive therapy. DE-ESCALATE is one of three research projects coordinated by EORTC, alongside @LEGATO and @STREXIT- 2 Project, which have received funding from the Horizon Europe Programme. The study is in collaboration with Syreon Research Institute and will have a duration of five years.

We thank everyone involved for their contributions to these important research initiatives.

You can also help support EORTC’s game-changing clinical research to unleash scientific breakthrough and transform cancer patients’ lives. Learn how to GET INVOLVED, or Make a Contribution Now.